• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Biosergen

7.60 SEK

-6.17 %

Less than 1K followers

BIOSGN

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-6.17 %
-19.58 %
-80.21 %
-80.77 %
-84.20 %
-86.94 %
-88.42 %
-
-97.94 %

Biosergen is active in biotechnology. The company specializes in the research and development of antifungal drugs. The product portfolio includes, for example, an antifungal drug for the treatment of invasive fungal infections in immunosuppressed patients. The company collaborates with research institutes and pharmaceutical companies internationally. Biosergen was founded in 2004 and is headquartered in Solna.

Read more
Market cap
17.85M SEK
Turnover
17.64K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
30.6.
2026

General meeting '26

30.6.
2026

Interim report Q1'26

19.8.
2026

Interim report Q2'26

Regulatory press release5/28/2026, 6:30 AM

Notice of annual general meeting in Biosergen AB

Biosergen
Press release4/7/2026, 12:24 PM

BioStock: Biosergen halts BSG005 development

Biosergen
Regulatory press release4/4/2026, 7:00 PM

Biosergen AB: Biosergen Pauses Development of BSG005

Biosergen

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release2/10/2026, 7:30 AM

Biosergen AB: Biosergen publishes interim report for the fourth quarter 2025

Biosergen
Regulatory press release11/20/2025, 7:30 AM

Biosergen AB: Determination of Record Date for Reverse Share Split in Biosergen

Biosergen
Press release11/19/2025, 1:54 PM

BioStock: Biosergen comments on continued progress in the third quarter

Biosergen
Regulatory press release11/19/2025, 7:30 AM

Biosergen AB: Biosergen publishes interim report for the third quarter 2025

Biosergen
Regulatory press release10/28/2025, 7:30 AM

Biosergen AB: Biosergen's Nomination Committee appointed

Biosergen
Press release9/22/2025, 11:43 AM

BioStock: ECDC sounds alarm on C. auris – Biosergen eyes role in containment

Biosergen
Press release9/17/2025, 10:04 AM

Carlsquare: Mrkt BUZZ, Biosergen: Candidozyma auris on the rise in Europe

Biosergen
Press release9/2/2025, 1:40 PM

Carlsquare: Research update Biosergen: Ongoing development going according to plan

Biosergen
Press release8/21/2025, 7:52 AM

BioStock: Biosergen’s CEO on the preparations for the next clinical phase

Biosergen
Regulatory press release8/20/2025, 6:30 AM

Biosergen AB: Biosergen publishes its interim report for the second quarter 2025

Biosergen
Press release7/25/2025, 10:16 AM

BioStock: Biosergen strengthens executive team amid clinical momentum

Biosergen
Regulatory press release7/24/2025, 12:12 PM

Biosergen AB: Biosergen Appoints Mark Beveridge as Chief Financial Officer

Biosergen
Regulatory press release6/11/2025, 10:01 AM

Bulletin from the annual general meeting in Biosergen AB (publ)

Biosergen
Press release5/23/2025, 8:00 AM

Carlsquare: Research update Biosergen: Stable quarter with exciting news around the corner

Biosergen
Press release5/21/2025, 1:47 PM

BioStock: Biosergen advances antifungal drug with strong Q1 results

Biosergen
Regulatory press release5/21/2025, 6:30 AM

Biosergen AB: Biosergen publishes interim report for the first quarter 2025

Biosergen
Press release5/12/2025, 11:45 AM

BioStock: Biosergen taps antifungal expert as board member

Biosergen